KRAS and non-small cell lung carcinoma: Similar alterations in cell signaling, autophagy, and viability data were obtained treating A549 NSCLC cells with the drug combination that expresses a mutant K-RAS protein and erlotinib-resistant HCC827 cells (Figure 4; Supplementary Figure S5).